Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 2429-2438

  Soares, Rui S ^a,f   Tendeiro, Rita ^a   Foxall, Russell B ^a   Baptista, António P ^a   Cavaleiro, Rita ^a   Gomes, Perpétua ^b,c,d   Camacho, Ricardo ^b,d   Valadas, Emília ^e   Doroana, Manuela ^e   Lucas, Margarida ^e   Antunes, Francisco ^e   Victorino, Rui M M ^a,e   Sousa, Ana E ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b HOSPITAL EGAS MONIZ   (Portugal)

^c INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^d Instituto Superior de Higiene e Medicina Tropical   (Portugal)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS EMTRICITABINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MESSENGER RNA; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; FEMALE; GENE DOSAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNE RESPONSE; MALE; PLASMA CELL; PRIORITY JOURNAL; RNA COPY; RNA TRANSCRIPTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSCRIPTION;

ADULT; AGED; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; VIREMIA; VIRUS REPLICATION; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 79551712331     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01921-10     Document Type: Article

References (62)

1. Adje-Toure, C. A., et al. 2003. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17(Suppl. 3): S49-S54. (Pubitemid 36951669)
2. Adjorlolo-Johnson, G., et al. 1994. Prospective comparison of mother-tochild transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 272:462-466. (Pubitemid 24235696)
3. Andersson, S., et al. 2000. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch. Intern. Med. 160:3286-3293.
4. Bagnarelli, P., et al. 1996. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J. Virol. 70:7603-7613. (Pubitemid 26339065)
5. Berry, N., et al. 1998. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J. Hum. Virol. 1:457-468.
6. Berry, N., et al. 1994. HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4+ lymphopenia in HIV type 2-infected individuals. AIDS Res. Hum. Retroviruses 10:1031-1037.
7. Brandin, E., et al. 2003. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 19:543-550.
8. Brenchley, J. M., et al. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J. Virol. 78:1160-1168. (Pubitemid 38095826)
9. Cavaleiro, R., et al. 2009. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog. 5:e1000667.
10. Chun, T. W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
11. Chun, T. W., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
12. Clavel, F., et al. 1987. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N. Engl. J. Med. 316:1180-1185.
13. Colson, P., et al. 2005. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J. Med. Virol. 75:381-390.
14. Colson, P., et al. 2004. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J. Clin. Microbiol. 42:570-577.
15. Damond, F., et al. 2005. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J. Clin. Microbiol. 43:484-487.
16. Desbois, D., et al. 2008. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob. Agents Chemother. 52:1545-1548.
17. Dinoso, J. B., et al. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 106:9403-9408.
18. Douek, D. C., et al. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98. (Pubitemid 34498823)
19. Drylewicz, J., et al. 2008. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 22:457-468. (Pubitemid 351317287)
20. Ferns, R. B., and J. A. Garson. 2006. Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control. J. Virol. Methods 135:102-108.
21. Fischer, M., et al. 2008. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5:107.
22. Furtado, M. R., L. A. Kingsley, and S. M. Wolinsky. 1995. Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J. Virol. 69:2092-2100.
23. Garrigue, I., et al. 2000. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS 14:2851-2855. (Pubitemid 32042748)
24. Gomes, P., et al. 1999. Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. J. Clin. Microbiol. 37:453-456.
25. Gottlieb, G. S., et al. 2009. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin. Infect. Dis. 48:476-483.
26. Gottlieb, G. S., et al. 2006. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 20:895-900. (Pubitemid 43731572)
27. Grabar, S., et al. 2009. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 23:1163-1169.
28. Grossman, Z., M. Meier-Schellersheim, A. E. Sousa, R. M. Victorino, and W. E. Paul. 2002. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat. Med. 8:319-323.
29. Jallow, S., et al. 2009. Virological response to highly active antiretroviral therapy (HAART) in HIV-2 and HIV-1/HIV-2 dually infected patients in the Gambia and the emergence of drug-resistant variants. J. Clin. Microbiol. 47:2200-2208.
30. Kanki, P. J., et al. 1994. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343:943-946. (Pubitemid 24117229)
31. Kim, S. Y., R. Byrn, J. Groopman, and D. Baltimore. 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63:3708-3713. (Pubitemid 19205441)
32. Klotman, M. E., et al. 1991. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc. Natl. Acad. Sci. U. S. A. 88:5011-5015.
33. Leligdowicz, A., et al. 2010. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J. Infect. Dis. 201:114-122.
34. MacNeil, A., et al. 2007. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J. Virol. 81:5325-5330. (Pubitemid 46744441)
35. Marlink, R., et al. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590. (Pubitemid 24308975)
36. Matheron, S., et al. 2003. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 17:2593-2601. (Pubitemid 38402337)
37. Michael, N. L., et al. 1995. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J. Virol. 69:1868-1877.
38. Michael, N. L., et al. 1991. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J. Virol. 65:1291-1303.
39. Michael, N. L., M. Vahey, D. S. Burke, and R. R. Redfield. 1992. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J. Virol. 66:310-316.
40. Mullins, C., et al. 2004. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin. Infect. Dis. 38:1771-1779.
41. Ntemgwa, M. L., T. d'Aquin Toni, B. G. Brenner, R. J. Camacho, and M. A. Wainberg. 2009. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob. Agents Chemother. 53:3611-3619.
42. Okulicz, J. F., et al. 2009. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J. Infect. Dis. 200:1714-1723.
43. Palmer, S., et al. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
44. Pereyra, F., et al. 2009. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 200:984-990.
45. Popper, S. J., et al. 2000. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J. Virol. 74:1554-1557. (Pubitemid 30044108)
46. Popper, S. J., et al. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180:1116-1121.
47. Rodés, B., et al. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38:1370-1374.
48. Ruelle, J., et al. 2008. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect. Dis. 8:21.
49. Seshamma, T., O. Bagasra, D. Trono, D. Baltimore, and R. J. Pomerantz. 1992. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 89:10663-10667.
50. Simon, F., et al. 1993. Cellular and plasma viral load in patients infected with HIV-2. AIDS 7:1411-1417. (Pubitemid 23333828)
51. Smith, N. A., et al. 2001. Antiretroviral therapy for HIV-2 infected patients. J. Infect. 42:126-133. (Pubitemid 32631814)
52. Soares, R., et al. 2006. Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J. Virol. 80:12425-12429. (Pubitemid 44904396)
53. Sonza, S., et al. 2002. Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocytederived macrophages. J. Virol. 76:12611-12621. (Pubitemid 35386946)
54. Soriano, V., et al. 2000. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J. Med. Virol. 61:111-116.
55. Sousa, A. E., J. Carneiro, M. Meier-Schellersheim, Z. Grossman, and R. M. Victorino. 2002. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169:3400-3406.
56. van der Ende, M. E., et al. 2003. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 17(Suppl. 3):S55-S61.
57. Vesanen, M., M. Markowitz, Y. Cao, D. D. Ho, and K. Saksela. 1997. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Virology 236:104-109. (Pubitemid 27410357)
58. Viard, J. P., et al. 2004. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18:45-49.
59. Vitone, F., D. Gibellini, P. Schiavone, and M. C. Re. 2005. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J. Clin. Virol. 33:194-200.
60. Walker, B. D. 2007. Elite control of HIV infection: implications for vaccines and treatment. Top. HIV Med. 15:134-136.
61. Witvrouw, M., et al. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.
62. Zanchetta, M., et al. 2006. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J. Infect. Dis. 193:1718-1727.